Ulcerative colitis.

@article{Danese2011UlcerativeC,
  title={Ulcerative colitis.},
  author={Silvio Danese and Claudio Fiocchi},
  journal={The New England journal of medicine},
  year={2011},
  volume={365 18},
  pages={
          1713-25
        }
}
 Is medical clearance required? .................................. Possibly (e.g., if the disease is unstable — flare-up — and/or there are active oral lesions). Also, medical clearance may be required if patient/client is being treated with medications associated with immunosuppression +/increased risk of infection (e.g., corticosteroids [e.g., prednisone], azathioprine, 6-mercaptopurine, methotrexate, cyclosporine, sulfasalazine, biologic response modifier drugs [e.g., anti-tumour necrosis… Expand

Paper Mentions

Interventional Clinical Trial
Together with Crohn's disease (CD), ulcerative colitis (UC) is one of the major forms of inflammatory bowel diseases (IBD).Currently, no curative therapy is available, since the… Expand
ConditionsAutoimmune Diseases, Ulcerative Colitis
InterventionBiological
Interventional Clinical Trial
Epidemiological studies suggest that daily intake of fruits and vegetables high in polyphenols or the addition of olive oil containing many polyphenols is associated with a… Expand
ConditionsUlcerative Colitis Chronic Mild
InterventionCombination Product
Observational Clinical Trial
To assess if infliximab drug levels in subjects with Ulcerative Colitis predict risk of colectomy rate. Additionally, the investigators will estimate an optimal day 4 infliximab… Expand
ConditionsColitis, Ulcerative, IBD, Inflammatory Bowel Disease
Biological Agents for Moderately to Severely Active Ulcerative Colitis
TLDR
A systematic review of randomized, controlled trials assessing biological agents as induction or maintenance therapy for moderately to severely active UC in adults to address this issue and compare the different treatment options. Expand
Positioning therapies in ulcerative colitis.
TLDR
A review of the literature is conducted to provide an up-to-date overview of the available evidence on this topic and suggest the optimal position of therapies in these algorithms remains unclear. Expand
Medical therapy versus surgery in moderate-to-severe ulcerative colitis.
TLDR
An overview of currently available treatment options for patients with moderate-to-severe ulcerative colitis is provided and factors that should be considered during the therapeutic decision are summarized. Expand
TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES.
TLDR
A patient with active ulcerative colitis with primary non-response to three biologics, with different mechanisms of action, who refused surgical treatment and had a favorable response to tofacitinib with clinical and endoscopic remission is reported. Expand
Immunosuppressive and biologic therapy for ulcerative colitis
TLDR
There is a need for optimizing and renewing the traditional therapeutic approach to UC, and new therapies beyond conventional treatment options possibly aiming to change the poor clinical course of many patients with ulcerative colitis. Expand
Inflammatory bowel disease and targeted oral anti-TNFα therapy.
TLDR
Regulating the actions of the pro-inflammatory cytokine human tumor necrosis factor-alpha (hTNF α) through the use of anti-TNFα monoclonal antibodies has proven an effective intervention for IBD with their increased use a testament of their effectiveness. Expand
Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges
TLDR
Data is summarized regarding AJM300, phosphatidylcholine (LT-02), mongersen, ozanimod, filgotinib and tofacitinib, which were tested in clinical trials for both Crohn’s disease and ulcerative colitis. Expand
Ulcerative Colitis.
TLDR
To minimize the complications of UC and adverse events from medications, a working collaboration between primary care physicians and gastroenterologists is necessary to make sure that vaccinations are optimized and that patients are screened for colon cancer, skin cancer, bone loss, depression, and other treatable and preventable complications. Expand
Inflammatory pathways of importance for management of inflammatory bowel disease.
TLDR
The major signaling pathways of clinical importance for IBD therapy are elucidated and several new treatment options are under development for the treatment of CD and UC, however, no drug fits all patients. Expand
Skin Manifestations of Inflammatory Bowel Disease
TLDR
Current knowledge on cutaneous EIMs, their diagnostic criteria and clinical presentation, natural history, pathogenesis, and treatment options are summarized. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 104 REFERENCES
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?
TLDR
Preliminary evidence suggests that a substantial proportion of patients in clinical remission for >1 year, without signs of active inflammation can remain in remission after stopping treatment, and there are insufficient data to make recommendations on when to stop anti-TNF therapy. Expand
Exacerbation of ulcerative colitis after rituximab salvage therapy
TLDR
The data suggest an important anti‐ rather than proinflammatory role of B‐cells in UC, which is in contrast to rheumatoid arthritis patients, rituximab had deleterious effects in this UC patient by blocking IL‐10 producing B‐ cells. Expand
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.
TLDR
This research highlights the need to understand more fully the role of microbiota in the development of Crohn's and Colitis and the role that language plays in the management of these conditions. Expand
Biological therapies for inflammatory bowel diseases.
TLDR
Infliximab, a chimeric immunoglobulin (Ig)G1 monoclonal antibody to tumor necrosis factor, dramatically improved treatment of patients with Crohn's disease and ulcerative colitis and has achieved treatment goals such as mucosal healing and decreasing the need for hospitalizations and surgeries. Expand
European evidence-based Consensus on the management of ulcerative colitis: Current management.
TLDR
The simplest, best validated and most widely used index for identifying acute severe UC remains that of Truelove & Wi_tts 3: any patient who has a bloody stool frequency ≥ 6/day and a tachycardia and temperature > 37.8 °C, or anaemia has severe ulcerative colitis. Expand
Diagnostic Standards in the Pathology of Inflammatory Bowel Disease
TLDR
A high degree of awareness by clinicians and pathologists is required in order to miss these life-threatening complications of IBD, and the use of modern immunosuppressive therapies may go along with an increased susceptibility towards infections. Expand
Colectomy rate in acute severe ulcerative colitis in the infliximab era.
  • A. Aratari, C. Papi, +5 authors R. Caprilli
  • Medicine
  • Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2008
TLDR
Infliximab can avoid urgent colectomy in steroid-refractory patients but the risk of elective coLECTomy, in the long-term, is not modified. Expand
Update on the etiology, pathogenesis and diagnosis of ulcerative colitis
  • S. Hanauer
  • Medicine
  • Nature Clinical Practice Gastroenterology &Hepatology
  • 2004
TLDR
The diagnosis of ulcerative colitis is being aided by recent advances in diagnostic strategies, including the detection of fecal and serologic markers and the use of wireless capsule endoscopy, but, in the absence of a pathognomonic marker, the definition of this disease remains undefined. Expand
Suppression of inflammation in ulcerative colitis by interferon-β-1a is accompanied by inhibition of IL-13 production
TLDR
The data provide a proof-of-concept that IL-13 is an effector cytokine in ulcerative colitis and should be a target for novel therapies. Expand
Inflammatory bowel disease: the role of environmental factors.
TLDR
Smoking and the enteric bacterial flora are the ones for which the most solid evidence is currently available, and evidence for a major role of the diet in inducing or modifying IBD is limited, while that for nonsteroidal anti-inflammatory drugs is more convincing than for oral contraceptives. Expand
...
1
2
3
4
5
...